Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3237602 | 0.87 | GPR139 (0.50) | P2RX7MEN1KMT2AALDH1A1SLC6A9 | |
| SCHEMBL3233235 | 0.86 | MEN1 (0.42) | P2RX7MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL3238379 | 0.82 | ACLY (0.45) | MEN1KMT2AALDH1A1SLC6A9MAPK1 | |
| SCHEMBL3240099 | 0.82 | CRHR1 (0.46) | TYK2MEN1KMT2AANO1ALDH1A1 | |
| SCHEMBL3237145 | 0.81 | AVPR2 (0.43) | MEN1KMT2AALDH1A1SLC6A9LMNA | |
| SCHEMBL4356706 | 0.81 | LMNA (0.51) | SLC6A9MAPK1LMNA | |
| SCHEMBL4359374 | 0.81 | SLC6A9 (0.41) | MEN1KMT2ARAB9ASLC6A9LMNA | |
| SCHEMBL3244199 | 0.81 | MEN1 (0.49) | P2RX7MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL3238270 | 0.80 | ALDH1A1 (0.57) | MEN1KMT2ARAB9AALDH1A1SLC6A9 | |
| SCHEMBL3230762 | 0.80 | SLC6A9 (0.45) | MEN1KMT2AALDH1A1SLC6A9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| WO-2006067423-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287547-A1 | Glycine Transport Inhibitors | SLC18A2, SLC6A5, SLC1A2 | P2RX7 2285/4885P2RY12 2421/4885TYK2 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.